NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
Incyte Corporation
University of Michigan Rogel Cancer Center
Academic and Community Cancer Research United
pharmaand GmbH
Abramson Cancer Center at Penn Medicine
Bristol-Myers Squibb